Overview

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Status:
NOT_YET_RECRUITING
Trial end date:
2027-01-13
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety profile of dostarlimab in Indian adults with recurrent or advanced endometrial cancer.
Phase:
PHASE4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
dostarlimab